Foresight diagnostics to show vision of the new standard of lymphoma MRD detection at ICML
Foresight Diagnostics is presenting its proprietary PhasED-Seq technology at ICML for improved minimal residual disease (MRD) detection rates in diffuse large B-cell lymphoma (DLBCL) patients. The technology has been shown to detect relapsing disease 200 days earlier than current methods.